# Larry Cohen

> Larry Cohen, formally Lawrence K. Cohen, PhD, is the CEO of Health2047 and a former research leader and operating executive. His career includes leadership at Zyomyx, VIA Pharmaceuticals, Progenitor, Somatix, and Kadmon Holdings. He has led Health2047 since 2018 and works on the financing, formation, and growth of early-stage companies.

- **Role:** Chief Executive Officer at Health2047
- **Organizations:** Health2047, Kadmon Holdings, VIA Pharmaceuticals, Zyomyx, Progenitor, Inc., Somatix Therapy Corporation
- **Education:** B.A., Grinnell College, PhD in Microbiology, University of Illinois, Postdoctoral work in Molecular Biology, Dana-Farber Cancer Institute and Harvard Medical School Department of Biochemistry
- **Known for:** Led Zyomyx during its prototype partnership and integrated product release., Held president and CEO roles at both Zyomyx and VIA Pharmaceuticals., Has led Health2047 as CEO since 2018.

## Career timeline

- **mid-1980s** — Worked as a bench scientist, as recalled in his October 2024 interview.
- **2000** — Identified as Zyomyx chief operating officer during its December Series D financing.
- **2001** — Identified as Zyomyx CEO during its April partnership announcement with Axon Instruments.
- **2003** — President and CEO of Zyomyx at the release of its integrated biochip system.
- **2004** — An August employment agreement named him president, CEO, and treasurer of VIA Pharmaceuticals.
- **before 2017** — Served as Executive Vice President of Research and Business Development at Kadmon Holdings.
- **2017** — Joined Health2047.
- **2018** — Began his CEO tenure at Health2047, according to its current official biography.
- **2024** — Participated in the Global Innovation and Investment panel at dentech.
- **2025** — Contributed advice on board discussions focused on execution and progress.

## Achievements

- Led Zyomyx during its prototype partnership and integrated product release.
- Held president and CEO roles at both Zyomyx and VIA Pharmaceuticals.
- Has led Health2047 as CEO since 2018.
- Serves on boards of Health2047 portfolio companies.

## Latest updates

- **2026-03** — Named as moderator of a ViVE 2026 panel in a public NACHC event recap.
- **2025-11** — Quoted as Health2047 CEO in Evidium’s announcement of a $22 million Series A co-led by Health2047 and WGG Partners.
- **2025-04** — Contributed founder advice to Health2047’s article about establishing and using a board.

## Links

- Website: https://health2047.com/leadership/lawrence-k-cohen-phd/
- LinkedIn: https://www.linkedin.com/in/larrykcohen/

---

Profile page: https://yespress.io/larry-cohen
Published by YesPress — https://yespress.io
Last updated: 2026-10-10